A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered QCZ484 in Healthy Subjects and Subjects With Mild Hypertension
Sponsor: Novartis Pharmaceuticals
Listed as NCT06905327, this PHASE1 trial focuses on Mild Hypertension and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 5 times since 2023, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Adelaide, Australia
- • Auckland, New Zealand
- • Herston, Australia
- • Morayfield, Australia